Clearmind Medicine Inc. CMND
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -98.18%
- 1 year
- -99.59%
5D -1.74 (-36.40%)
- Market cap
- 1.33M
- EPS (ttm)
- -461.20
- Shares out
- 4.38M
- YTD return
- -98.18%
- 1-year return
- -99.59%
- 50-day average
- 1.39
- 200-day average
- 1.33
- Volume
- 10.20K
- Avg volume
- 55.50K
- Open
- 3.09
- Previous close
- 3.20
- Day's range
- 2.63 – 3.28
- 52-week range
- 2.63 – 694.40
- Beta
- -1.51
Key statistics
- Enterprise value
- -2.75M
- Price / book
- 1.40
- Free cash flow
- 162.86K
- Total cash
- 7.68M
- Total debt
- 60.90K
- Return on equity
- -267.90%
- Short % of float
- 4.72%
Fundamental scorecard
5 of 25 checks passed on CMND’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Jul 31, 2026.
Financials — quick view
About Clearmind Medicine Inc.
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders; and Dr. Glitter Pty Ltd to develop and commercialize the MEAI-based alcohol substitute and ActivCrystal technology. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- clearmindmedicine.com
News
12 Health Care Stocks Moving In Friday's Pre-Market Session Clearmind Medicine Publishes Hong Kong Patent Application Covering Innovative Psychedelic Compounds Targeting Treatment Of PTSD And Other Mental Health Disorders
Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication Clearmind Medicine Completes Patient Enrollment For Part C Of Ongoing Phase I/IIa Clinical Trial Evaluating CMND-100
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
12 Health Care Stocks Moving In Friday's Pre-Market Session Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder
Your note
Sign in to keep a note on CMND — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gotham Asset Management, LP | 10.70% | 339,008 | 413.59K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 5.38% | 170,641 | 208.18K | Sep 29, 2024 |
| UBS Group AG | 4.46% | 141,337 | 172.43K | Sep 29, 2024 |
| Cornerstone Wealth Group, LLC | 0.63% | 20,000 | 24.40K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.56% | 17,729 | 21.63K | Sep 29, 2024 |
| HRT Financial LP | 0.40% | 12,756 | 15.56K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 6.74% | 213,764 | 260.79K | Oct 30, 2024 |
